Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical
Keywords: پایه; apremilast; difficult to treat; ESTEEM; moderate to severe; palmoplantar psoriasis; palms; PSOR-005; soles; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; IL; interleukin; m-PPPASI; modified Palmoplantar Psoriasis Are